June 6th 2023
The companies have noted that the decision was not made because of safety or efficacy data, but to refocus efforts on the ongoing phase 2b LUMA trial of BIIB122.
Addressing Healthcare Inequities in Stroke Care: How Can We Play an Active Role in Improving Outcomes for All Patients?
View More
Applying Precision Medicine: Improving Care for Patients with Motor Complications of Parkinson Disease
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
BURST CME™: Taking ALS Management to the Next Level
View More
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
View More
Taking Pompe Disease Management to the Next Level: Optimizing Clinical Assessments and Treatment Decision-Making
View More
From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease
View More
Post-COVID Abnormal Sleep is Common, With Potential Impacts on Cognition
Among patients with post-acute sequelae from COVID-19 infection, self-reported cognitive symptoms were correlated with severity of fatigue, anxiety, and depression, but not subjective sleep disturbance.
Solriamfetol Improves Cognition in Patients With Obstructive Sleep Apnea
In a study of 59 individuals with obstructive sleep apnea, solriamfetol yielded cognitive improvements at post-dose time points throughout the day, along with improvements in Patient Global Impression of Severity.
NeurologyLive® Brain Games: June 4, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Sleep Medicine.
Certain Factors May Assist in Predicting Clinical Phenotype Following Optic Neuritis
Factors such as older age, poor steroid responsiveness, and plasma exchange were associated with NMOSD phenotype, while normal or thinned retinal nerve fiber layer and short-segment hyperintensity were associated with idiopathic optic neuritis.
CMS Announces Plan to Provide Coverage of Antiamyloid Therapies for Alzheimer Disease
In July, the FDA is expected to make a decision on lecanemab (Leqembi), an antiamyloid therapy previously approved under the accelerated approval pathway, for a potential traditional approval for early-stage Alzheimer disease.